chrisvoncsefalvay/vaers-outcomes huggingface dataset:
rather severe shaking, shortness of breath, increased heart rate, chills (but no measurable fever), weakness. Acute symptoms lasted a few hours (4-5), all noticeable symptoms were gone after about 24 hours.
Tinnitus in both ears 2 weeks after first Booster; Decrease in hearing in both ears  2 weeks after first Booster; This spontaneous case was reported by a consumer and describes the occurrence of TINNITUS (Tinnitus in both ears 2 weeks after first Booster) and HYPOACUSIS (Decrease in hearing in both ears  2 weeks after first Booster) in a 68-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     Previously administered products included for Product used for unknown indication: J & J Covid 19 Vaccine (1 primary dose) on 05-Mar-2021. Past adverse reactions to the above products included No adverse event with J & J Covid 19 Vaccine.    On 29-Oct-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 12-Nov-2021, the patient experienced TINNITUS (Tinnitus in both ears 2 weeks after first Booster) and HYPOACUSIS (Decrease in hearing in both ears  2 weeks after first Booster). At the time of the report, TINNITUS (Tinnitus in both ears 2 weeks after first Booster) and HYPOACUSIS (Decrease in hearing in both ears  2 weeks after first Booster) had not resolved.            No concomitant medication was provided by the reporter.  On 29 Oct 2021 patient received first Moderna booster dose of vaccine. It was reported that about 2 weeks after the first booster, patient started having tinnitus, and decrease in hearing in both ears. These side effects never went away and patient did not call the doctor.  No treatment medication was provided by the reporter.   This case was linked to MOD-2022-550323 (Patient Link).
Flu like symptoms; This is a spontaneous report from a contactable consumer reported for herself. A 68-years-old female patient received first dose of bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE, lot number: EL3246), via an unspecified route of administration at Left arm on 12Jan2021 16:00 at SINGLE DOSE for covid-19 immunization. Medical history included Hypo-Thyroid and gastrooesophageal reflux disease. No known allergies, not allergies to medications, food, or other products. The patient received other medications the patient received within 2 weeks of vaccination. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. The patient experienced non-serious flu like symptoms three days after vaccine on 15Jan2021 at 04:00 PM, lasted for 4 days. No treatment received for the event. Prior to vaccination, the patient was not diagnosed with COVID-19. Covid (Nasal Swab) tested on 19Jan2021 post vaccination but the result was pending. The outcome of the event was recovering.
After patient received her 3 injections, she became pale and started slumping over.  As mom and RN were helping her lay down they noticed her eyes deviating to the right and twitching of her mouth for no more than 15 seconds.  She woke up right away and was appropriated.  Vasovagal syncope.
pt recv vax; child found not breathing in morning; ambulance was ER and resuscitation was tried;
No temperature but feeling feverish, diarrhea, headache, muscle pain, chills. Started in the morning on 4/6/2022 and now I have to stay home from work for two days.
Information has been received from a physician concerning a 17 year old female patient with no previous medical history and allergies reported, who on 06-JUN-2007 was vaccinated with the first dose of GARDASIL 0.5 mL. On 22-OCT-2008, the patient was vaccinated with the second dose of GARDASIL (Lot # not provided) 0.5 mL. On 22-OCT-2008, the patient developed severe allergic reactions like unresponsiveness, in and out consciousness, heart rate down to 62 and cold immediately. On an unknown date, the patient recovered. The patient sought unspecified medical attention. The patient's adverse events were considered to be immediately life-threatening by the physician. Additional information is expected.
318 patients received dose from vials beyond 30-day use by date; This spontaneous case was reported by a nurse and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (318 patients received dose from vials beyond 30-day use by date) in a 40-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 037C21A) for COVID-19 vaccination.     No Medical History information was reported.    On 17-Aug-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 17-Aug-2021, the patient experienced EXPIRED PRODUCT ADMINISTERED (318 patients received dose from vials beyond 30-day use by date). On 17-Aug-2021, EXPIRED PRODUCT ADMINISTERED (318 patients received dose from vials beyond 30-day use by date) had resolved. Not Provided      For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No relevant concomitant medications were reported.  No treatment information was provided.
Patient rec'd Moderna vaccine on 1/19/21 and later developed facial swelling (not at pharmacy).  Patient went to ER and told ER she felt that facial swelling was due to Covid vaccine, but ER told her fatigue was her problem.  Patient rec'd 2 bags of solution to rehydrate her.  Facial swelling resolved within a day.
Patient had vaso vagal episode 1-2 minutes after receiving the vaccine in the left arm. He was operating his vehicle and crashed into another parked car. When I arrived to the patient he was alert and oriented, not in any acute distress, he did suffer a minor abrasion on the left arm. Patients vitals were stable during his stay in observation.
Can one get SHINGLES ,after the vaccine/suspected vaccination failure; shingles; This case was reported by a consumer via interactive digital media and described the occurrence of vaccination failure in a patient who received Herpes zoster (Shingles vaccine) for prophylaxis.   On an unknown date, the patient received Shingles vaccine. On an unknown date, unknown after receiving Shingles vaccine, the patient experienced vaccination failure (serious criteria GSK medically significant) and shingles. On an unknown date, the outcome of the vaccination failure and shingles were unknown.   It was unknown if the reporter considered the vaccination failure and shingles to be related to Shingles vaccine.     Additional Information: GSK receipt date: 11-Sept-2022 Reporter's comment: The case was received from the patient via interactive digital media. The patient asked that could one get shingles, after receiving the shingles vaccine. Additional supportive information: This case was considered as suspected vaccination failure since the details regarding the completion of primary vaccination schedule, time to onset and laboratory confirmation of shingles were unknown at the time of reporting. The follow-up could not be possible as no contact details were available.
Tiredness/ Fatigue; Muscle aches; Dizziness; Headache; Nausea; Injection soreness that had faded after 2 days; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 57 year-old female patient (not pregnant) received bnt162b2 (BNT162B2), administered in arm left, administration date 18Mar2021 02:30 (Batch/Lot number: unknown) at the age of 57 years as dose 1, single for covid-19 immunisation. The patient had no relevant medical history. Concomitant medication(s) included: ZINC; GINKOBA; CALCIUM; MAGNESIUM; VITAMIN B; VITAMIN C [ASCORBIC ACID]; VITAMIN D NOS. The following information was reported: VACCINATION SITE PAIN (non-serious) with onset 20Mar2021 15:45, outcome "recovered" (22Mar2021 15:45), described as "Injection soreness that had faded after 2 days"; FATIGUE (non-serious) with onset 22Mar2021, outcome "not recovered", described as "Tiredness/ Fatigue"; MYALGIA (non-serious) with onset 22Mar2021, outcome "not recovered", described as "Muscle aches"; DIZZINESS (non-serious) with onset 22Mar2021, outcome "not recovered", described as "Dizziness"; HEADACHE (non-serious) with onset 22Mar2021, outcome "not recovered", described as "Headache"; NAUSEA (non-serious) with onset 22Mar2021, outcome "not recovered", described as "Nausea". Relevant laboratory tests and procedures are available in the appropriate section. Therapeutic measures were not taken as a result of vaccination site pain, fatigue, myalgia, dizziness, headache, nausea.  Additional Information:  The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. Prior to vaccination, the patient was not diagnosed with COVID-19. The patient experienced tiredness/ fatigue, muscle aches, dizziness, headache and nausea from Day 4 (22Mar2021) to Day 7 (25Mar2021) after the shot.  On Day 07,tiredness/ fatigue, muscle aches, dizziness, headache and nausea were worse. The patient was a part of a weekly CDC asymptomatic COVID-19 testing program at the (name withheld) university. The adverse events did not result in a visit to the doctors or other healthcare professional office/clinic visit, and emergency room/department or urgent care.  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
Pain in my right and in my left finger, in my left hand index finger; rashes on my left side of my stomach; I got like a pinched nerve that affects really bad in my left hand; This is a spontaneous report from a contactable consumer (patient). A 78-year-old patient of unspecified gender received BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE; lot number: EN6207), via an unspecified route of administration in the right arm on 18Mar2021 (at the age of 78-year-old), dose 2, single for COVID-19 immunisation. Medical history included diabetes. The patient was taking different kind of unspecified concomitant medications. Historical vaccine included BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE; lot number: EN6198) administered via an unspecified route of administration in the right arm on 25Feb2021 (at the age of 78-year-old), dose 1, single for COVID-19 immunisation. It was reported that the patient might have side effects from the COVID-19 vaccine. On 24Mar2021, the patient had a pain in right and in left finger, in the left-hand index finger. The patient gave "Sulphur" (not clarified) a test for blood glucose test for blood sugar test and few days later, got this pain and this pain went away and as of this report, the patient got a rashes on left side of stomach. The patient stated it was like got a pinched nerve that affects really bad in the left hand. The patient wanted to know, what could be done and how long. The patient was going in next month on 08Apr2021 for a surgery on mouth, to get a few teeth removed. The patient just wanted to find out if this would affect surgery. The outcome of the event pain in right and in left finger, in the left-hand index finger was recovered in Mar2021 and outcome of other events was unknown.  No follow-up attempts are possible; No further information is expected.
15.5  hours after I got my shot I got a fever of 104.7 which lasted for 6 hours.  My doctor told me to take 1 ibuprofen with some more tylenol and it went down to 102.  It was 101-102 for two more days and about 99.7 for two more days.  Then it was gone.
On 31MAR92 p/vax recvd pt became lethargic which lasted 48 rs; lt arm became limp day p/inject lasted all day 1APR92, until 2APR92 8PM; ON 1APR92 pt taken to ER for tx of arm; xrays were taken-no dislocation;
Chilling, Temp 101.4 ax, legs aching, temp oral 100.5   Fever and aching treated with Tylenol and Ibuprofen.
sore arm; Didn't sleep well; Wasn't feeling well; bodyaches; Fever; Headache; This spontaneous case was reported by a consumer and describes the occurrence of PAIN IN EXTREMITY (sore arm), SLEEP DISORDER (Didn't sleep well), MALAISE (Wasn't feeling well), MYALGIA (bodyaches) and PYREXIA (Fever) in a 67-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 031M20A and 039K20A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     The patient's past medical history included Hypothyroidism and Acid reflux (esophageal). Concurrent medical conditions included Penicillin allergy, Zinc sulfate turbidity abnormal and Drug allergy (Allergy to Zofran drug.). Concomitant products included PANTOPRAZOLE and LEVOTHYROXINE SODIUM (SYNTHROID) for an unknown indication.   On 20-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 23-Feb-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 23-Feb-2021, the patient experienced PAIN IN EXTREMITY (sore arm), SLEEP DISORDER (Didn't sleep well), MALAISE (Wasn't feeling well), MYALGIA (bodyaches), PYREXIA (Fever) and HEADACHE (Headache). At the time of the report, PAIN IN EXTREMITY (sore arm), SLEEP DISORDER (Didn't sleep well), MALAISE (Wasn't feeling well), MYALGIA (bodyaches), PYREXIA (Fever) and HEADACHE (Headache) outcome was unknown.            Treatment information was unknown. Action taken with mRNA-1273 in response to the event was not applicable.   This case was linked to MOD-2021-024239, MOD-2021-053240 (Patient Link).
A report was received from a consumer through their insurance company on 11/20/03 who is a female vaccinee of unspecified age who blacked out while driving her automobile, seven minutes after receiving Fluvirin on 10/20/03. On 10/20/03 the vaccinee blacked out while driving her automobile as a result of the vaccinee hit a fire hydrant. At the time of the report the outcome was not reported. Update 2/9/04: A follow up report was received from a health care professional indicating that the vaccinee was treated and released by an emergency department. The reporter did not see the vaccinee before, during or immediately after the incident. Follow up pending.
12:28pm consult requested by pt s/p vaccination 4/9/23 MODERNA BOOSTER (previous JJ primary series). reports heart fluttering q few hours, fever, flu like symptoms, bilateral leg soreness/pain, and sore injection site. ADR has improved since but consulted pt to monitor heart ADR and consult MD again (already consulted MD)  if persists. VAERS reported 4/18
Started to have chest pains a few days after vaccine. I passed out and was unresponsive with no pulse and breathing. Received cpr from my partner who found me on the floor at approximately 2:00am on 5/16/21.  I was taken to the emergency room of the hospital and underwent extensive tests of the brain: CT scan, MRI, Angiogram, and Spinal Puncture. All tests negative. I cannot walk without a walker and have other cognitive neurological symptoms. I was discharged from hospital on 6/2/21 to sub-acute rehabilitation facility. I was discharged from rehab on 6/12/21.  Neurological and neuromuscular symptoms are still present.
Red rash Warm to touch raised knot size of baseball, iced it took Tylenol
Patients administered with vaccine refrigerated temperature at 2° to 8°C longer than 30 days; Patients administered with vaccine refrigerated temperature at 2° to 8°C longer than 30 days; Based on the current case data, this case has been classified as invalid. This spontaneous case was reported by a pharmacist and describes the occurrence of WRONG TECHNIQUE IN PRODUCT USAGE PROCESS (Patients administered with vaccine refrigerated temperature at 2° to 8°C longer than 30 days) and PRODUCT STORAGE ERROR (Patients administered with vaccine refrigerated temperature at 2° to 8°C longer than 30 days) in a patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced WRONG TECHNIQUE IN PRODUCT USAGE PROCESS (Patients administered with vaccine refrigerated temperature at 2° to 8°C longer than 30 days) and PRODUCT STORAGE ERROR (Patients administered with vaccine refrigerated temperature at 2° to 8°C longer than 30 days). At the time of the report, WRONG TECHNIQUE IN PRODUCT USAGE PROCESS (Patients administered with vaccine refrigerated temperature at 2° to 8°C longer than 30 days) and PRODUCT STORAGE ERROR (Patients administered with vaccine refrigerated temperature at 2° to 8°C longer than 30 days) had resolved. Not Provided      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   Concomitant product use was not provided by the reporter.   Treatment information was not provided.
Patient passed out and began seizing within 5 minutes of vaccine administration sitting down on chair. Tonic, clonic motions for 5 seconds. No foaming at the mouth. Patient was taken off chair, held on the ground until seizure ended. Patient gained consciousness after a minute. Given water, snacks, air and EMS was called. EMS assessed situation, and allowed patient's girlfriend to pick him up from site and drive back home.
Extremely tired, Chills, headache, nausea.  Swollen arm with large lump and red warm rash
Rash on both hands; This is a spontaneous report received from a contactable reporter(s) (Pharmacist).  A 59 year-old female patient (not pregnant) received bnt162b2 (BNT162B2), intramuscular, administered in arm left, administration date 16Mar2021 (Batch/Lot number: unknown) at the age of 58 years as dose 1, single for covid-19 immunisation. Relevant medical history included: "Asthma" (unspecified if ongoing), notes: Other medical history: Asthma; "Hypertension" (unspecified if ongoing), notes: Other medical history: Hypertension; "Osteoarthritis" (unspecified if ongoing), notes: Other medical history: Osteoarthritis; "GERD" (unspecified if ongoing), notes: Other medical history: GERD; "Bone Spurs: Osteophyte" (unspecified if ongoing), notes: Other medical history: Bone Spurs; "Diverticulitis" (unspecified if ongoing), notes: Other medical history: Diverticulitis; "adhesive tape" (unspecified if ongoing), notes: Known allergies: adhesive tape. Concomitant medication(s) included: ALBUTEROL [SALBUTAMOL SULFATE]; AUGMENTIN [AMOXICILLIN SODIUM;CLAVULANATE POTASSIUM]; BUDESONIDE; ALPRAZOLAM; ESCITALOPRAM; SERTRALINE HYDROCHLORIDE; TRIAMTERENE HCTZ; PANTOPRAZOLE; METHOCARBAMOL; MONTELUKAST; KLOR-CON M20; ONDANSETRON; LISINOPRIL; MELOXICAM; OXYCODONE AND ACETAMINOPHEN; TRIAMCINOLONE [TRIAMCINOLONE ACETONIDE]; GABAPENTIN; VITAMIN D3; VITAMIN C ACID; FLUTICASONE; BREO ELLIPTA. Past drug history included: Cephalosporin, reaction(s): "Known allergies: Cephalosporins", notes: Known allergies: Cephalosporins; Gentamicin, reaction(s): "Known allergies: Gentamicin", notes: Known allergies: Gentamicin; Erythromycin, reaction(s): "Known allergies: Erythromycin", notes: Known allergies: Erythromycin; Floroquinolones, reaction(s): "Known allergies: Floroquinolones", notes: Known allergies: Floroquinolones; Asparagus, reaction(s): "Known allergies: Asparagus", notes: Known allergies: Asparagus. The following information was reported: RASH (non-serious) with onset 16Mar2021, outcome "recovered", described as "Rash on both hands". The event "rash on both hands" was evaluated at the physician office visit. Relevant laboratory tests and procedures are available in the appropriate section. Therapeutic measures were taken as a result of rash.  Additional information: The AE treatment received as a Triamcinolone Cream, No covid prior vaccination, tested for covid post vaccination with nasal swab on 30Dec2021 and covid test result was positive.  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
patients have been administered doses while the temperature excursion assessment was ongoing (possible temperature excursion); patients have been administered doses while the temperature excursion assessment was ongoing (possible temperature excursion); This spontaneous case was reported by an other health care professional and describes the occurrence of PRODUCT TEMPERATURE EXCURSION ISSUE (patients have been administered doses while the temperature excursion assessment was ongoing (possible temperature excursion)) and POOR QUALITY PRODUCT ADMINISTERED (patients have been administered doses while the temperature excursion assessment was ongoing (possible temperature excursion)) in a 60-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) .25 milliliter. On an unknown date, the patient experienced PRODUCT TEMPERATURE EXCURSION ISSUE (patients have been administered doses while the temperature excursion assessment was ongoing (possible temperature excursion)) and POOR QUALITY PRODUCT ADMINISTERED (patients have been administered doses while the temperature excursion assessment was ongoing (possible temperature excursion)). At the time of the report, PRODUCT TEMPERATURE EXCURSION ISSUE (patients have been administered doses while the temperature excursion assessment was ongoing (possible temperature excursion)) and POOR QUALITY PRODUCT ADMINISTERED (patients have been administered doses while the temperature excursion assessment was ongoing (possible temperature excursion)) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No concomitant medications was reported.  It was reported that there had been no power outages that would have impacted the Moderna vaccine. However, the Healthcare professional reiterated that because the facility was unable to download the digital data logger, they would need to treat the issue as a temperature excursion. The data logger was unable to download for the months of Dec-2021, Jan-2022, and Feb-2022. They were filling out a temperature excursion assessment at that time. It was reported that no adverse reactions were reported by any patient. Reporter confirmed that patients had administered doses while the temperature excursion assessment was ongoing.  No treatment drug details was reported   This case was linked to MOD-2022-501575 (Patient Link).
This spontaneous report was received from a physician via a company representative concerning a female patient in her "early teens" (exact age was unspecified). No information regarding the patient's concurrent medical conditions and medical history was provided. On an unknown dates, the patient was vaccinated with three doses of GARDASIL (dose, route of administration and lot# were not reported) or three doses of GARDASIL 9 (dose, route of administration and lot# were not reported) (unknown which vaccine was administered). The patient's concomitant medications were not reported. On an unknown date, the patient experienced an unspecified reaction after the first dose of GARDASIL or GARDASIL 9, which worsened after each of the subsequent doses. The patient sought medical attention and was being evaluated by unspecified specialists due to this unspecified reaction. The outcome of the unspecified reaction was reported as not recovered. The relatedness between the unspecified reaction and GARDASIL or GARDASIL 9 was not provided. Additional information has been requested.
Case completed 2 dose Covid vaccine series on 3/25/21, and ws then hospitalized for Covid on 8/24/21.
6cm diameter erythema/induration with irregular margins, warm and tender to touch. No streaking.